Bank of America Corp DE Sells 111,419 Shares of Glaukos Corp (GKOS)

Bank of America Corp DE trimmed its holdings in shares of Glaukos Corp (NYSE:GKOS) by 26.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 305,642 shares of the medical instruments supplier’s stock after selling 111,419 shares during the period. Bank of America Corp DE owned about 0.88% of Glaukos worth $12,421,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Swiss National Bank raised its stake in shares of Glaukos by 7.1% during the first quarter. Swiss National Bank now owns 27,000 shares of the medical instruments supplier’s stock valued at $832,000 after purchasing an additional 1,800 shares during the period. Great West Life Assurance Co. Can raised its stake in shares of Glaukos by 112.0% during the second quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock valued at $172,000 after purchasing an additional 2,240 shares during the period. Principal Financial Group Inc. raised its stake in shares of Glaukos by 10.2% during the first quarter. Principal Financial Group Inc. now owns 29,787 shares of the medical instruments supplier’s stock valued at $918,000 after purchasing an additional 2,746 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of Glaukos by 0.7% during the second quarter. Artisan Partners Limited Partnership now owns 426,246 shares of the medical instruments supplier’s stock valued at $17,323,000 after purchasing an additional 2,845 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its stake in shares of Glaukos by 19.6% during the second quarter. State Board of Administration of Florida Retirement System now owns 18,773 shares of the medical instruments supplier’s stock valued at $763,000 after purchasing an additional 3,070 shares during the period.

Shares of NYSE:GKOS opened at $58.86 on Friday. Glaukos Corp has a 12-month low of $23.08 and a 12-month high of $70.91.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $43.16 million during the quarter, compared to the consensus estimate of $40.51 million. Glaukos had a negative return on equity of 4.11% and a negative net margin of 3.49%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.10) EPS. Equities analysts expect that Glaukos Corp will post -0.55 EPS for the current fiscal year.

In other Glaukos news, CEO Thomas William Burns sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $38.78, for a total transaction of $5,817,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Chris M. Calcaterra sold 38,983 shares of the business’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $44.44, for a total transaction of $1,732,404.52. Following the sale, the chief operating officer now owns 278,983 shares of the company’s stock, valued at approximately $12,398,004.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 691,743 shares of company stock valued at $37,911,081. Insiders own 11.60% of the company’s stock.

GKOS has been the topic of a number of analyst reports. ValuEngine upgraded shares of Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. BMO Capital Markets lifted their price objective on shares of Glaukos from $59.00 to $62.00 and gave the company a “market perform” rating in a research note on Thursday, August 30th. JPMorgan Chase & Co. lowered shares of Glaukos from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 21st. Piper Jaffray Companies lifted their price objective on shares of Glaukos to $73.00 and gave the company an “overweight” rating in a research note on Friday, August 31st. Finally, Stephens reiterated an “overweight” rating and set a $57.00 price objective on shares of Glaukos in a research note on Wednesday, August 29th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $58.20.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Recommended Story: Analyst Ratings

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply